In contrast, the expense of orally administered harmine and other small molecule DYRK1A inhibitors is trivial in comparison, and GLP1R family drugs are already approved by regulatory agencies and in use in millions of people with T2D around the world. This evidence concerns the gene DYRK1A and type 2 diabetes mellitus.